Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Gender affirming hormonal treatment in Danish transgender persons: A nationwide register-based study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Glintborg, Dorte ; Rubin, Katrine Hass ; Kristensen, Simon Bang ; Lidegaard, Øjvind ; T'Sjoen, Guy ; Hilden, Malene ; Andersen, Marianne Skovsager. / Gender affirming hormonal treatment in Danish transgender persons : A nationwide register-based study. I: Andrology. 2022 ; Bind 10, Nr. 5. s. 885-893.

Bibtex

@article{3ee78d9376a045909f44a4f74166ffff,
title = "Gender affirming hormonal treatment in Danish transgender persons: A nationwide register-based study",
abstract = "BACKGROUND: Gender affirming hormonal treatment (GAHT) is a cornerstone in transgender care. National data are sparse regarding use of hormonal treatment by transgender persons.AIM: To assess use of GAHT in transgender persons.DESIGN: National register-based cohort study in Danish transgender persons followed from 2000 until 2018. The main outcome measure was prescription and purchase of GAHT. Persons with ICD-10 diagnosis code of {"}gender identity disorder{"} (CGI-cohort) and persons with legal sex change but without diagnosis (CPR-cohort) were included. In the CGI-cohort, transgender women were defined by prescription of estrogen and/or cyproterone acetate and/or testosterone-5-alpha reductase inhibitors, and transgender men were defined by prescription of testosterone after study inclusion. Discontinuation of GAHT was defined as no purchase of GAHT ≥13 months or shift from feminizing to masculinizing hormone treatment, or vice versa.RESULTS: The cohort included 2789 transgender persons (n = 1717, CGI-cohort and n = 1072, CPR-cohort). The median age (interquartile range) at study inclusion was 26.1 (17.7) years for persons assigned male at birth (n = 1447) and 22.5 (10.5) years for persons assigned female at birth (n = 1342). In the CGI-cohort, the event rate for GAHT in transgender women increased from 4.0 (95% confidence interval [CI]: [3.1; 5.2]) events per 100 person in year 2000-2005 to 20.6 (17.8; 23.7) between 2014 and 2018. In transgender men, the event rate of GAHT increased from 4.2 (2.8; 6.2) to 18.8 (16.4; 21.6). The rate of discontinuation of GAHT was 0.06 (95% CI 0.049; 0.071) per person year.CONCLUSIONS: The event rate of GAHT increased during 2000-2018. Our data suggested high adherence to GAHT.",
keywords = "Adult, Cohort Studies, Denmark/epidemiology, Female, Gender Identity, Humans, Male, Testosterone, Transgender Persons",
author = "Dorte Glintborg and Rubin, {Katrine Hass} and Kristensen, {Simon Bang} and {\O}jvind Lidegaard and Guy T'Sjoen and Malene Hilden and Andersen, {Marianne Skovsager}",
note = "{\textcopyright} 2022 The Authors. Andrology published by Wiley Periodicals LLC on behalf of American Society of Andrology and European Academy of Andrology.",
year = "2022",
month = jul,
doi = "10.1111/andr.13181",
language = "English",
volume = "10",
pages = "885--893",
journal = "Andrology",
issn = "2047-2919",
publisher = "Wiley",
number = "5",

}

RIS

TY - JOUR

T1 - Gender affirming hormonal treatment in Danish transgender persons

T2 - A nationwide register-based study

AU - Glintborg, Dorte

AU - Rubin, Katrine Hass

AU - Kristensen, Simon Bang

AU - Lidegaard, Øjvind

AU - T'Sjoen, Guy

AU - Hilden, Malene

AU - Andersen, Marianne Skovsager

N1 - © 2022 The Authors. Andrology published by Wiley Periodicals LLC on behalf of American Society of Andrology and European Academy of Andrology.

PY - 2022/7

Y1 - 2022/7

N2 - BACKGROUND: Gender affirming hormonal treatment (GAHT) is a cornerstone in transgender care. National data are sparse regarding use of hormonal treatment by transgender persons.AIM: To assess use of GAHT in transgender persons.DESIGN: National register-based cohort study in Danish transgender persons followed from 2000 until 2018. The main outcome measure was prescription and purchase of GAHT. Persons with ICD-10 diagnosis code of "gender identity disorder" (CGI-cohort) and persons with legal sex change but without diagnosis (CPR-cohort) were included. In the CGI-cohort, transgender women were defined by prescription of estrogen and/or cyproterone acetate and/or testosterone-5-alpha reductase inhibitors, and transgender men were defined by prescription of testosterone after study inclusion. Discontinuation of GAHT was defined as no purchase of GAHT ≥13 months or shift from feminizing to masculinizing hormone treatment, or vice versa.RESULTS: The cohort included 2789 transgender persons (n = 1717, CGI-cohort and n = 1072, CPR-cohort). The median age (interquartile range) at study inclusion was 26.1 (17.7) years for persons assigned male at birth (n = 1447) and 22.5 (10.5) years for persons assigned female at birth (n = 1342). In the CGI-cohort, the event rate for GAHT in transgender women increased from 4.0 (95% confidence interval [CI]: [3.1; 5.2]) events per 100 person in year 2000-2005 to 20.6 (17.8; 23.7) between 2014 and 2018. In transgender men, the event rate of GAHT increased from 4.2 (2.8; 6.2) to 18.8 (16.4; 21.6). The rate of discontinuation of GAHT was 0.06 (95% CI 0.049; 0.071) per person year.CONCLUSIONS: The event rate of GAHT increased during 2000-2018. Our data suggested high adherence to GAHT.

AB - BACKGROUND: Gender affirming hormonal treatment (GAHT) is a cornerstone in transgender care. National data are sparse regarding use of hormonal treatment by transgender persons.AIM: To assess use of GAHT in transgender persons.DESIGN: National register-based cohort study in Danish transgender persons followed from 2000 until 2018. The main outcome measure was prescription and purchase of GAHT. Persons with ICD-10 diagnosis code of "gender identity disorder" (CGI-cohort) and persons with legal sex change but without diagnosis (CPR-cohort) were included. In the CGI-cohort, transgender women were defined by prescription of estrogen and/or cyproterone acetate and/or testosterone-5-alpha reductase inhibitors, and transgender men were defined by prescription of testosterone after study inclusion. Discontinuation of GAHT was defined as no purchase of GAHT ≥13 months or shift from feminizing to masculinizing hormone treatment, or vice versa.RESULTS: The cohort included 2789 transgender persons (n = 1717, CGI-cohort and n = 1072, CPR-cohort). The median age (interquartile range) at study inclusion was 26.1 (17.7) years for persons assigned male at birth (n = 1447) and 22.5 (10.5) years for persons assigned female at birth (n = 1342). In the CGI-cohort, the event rate for GAHT in transgender women increased from 4.0 (95% confidence interval [CI]: [3.1; 5.2]) events per 100 person in year 2000-2005 to 20.6 (17.8; 23.7) between 2014 and 2018. In transgender men, the event rate of GAHT increased from 4.2 (2.8; 6.2) to 18.8 (16.4; 21.6). The rate of discontinuation of GAHT was 0.06 (95% CI 0.049; 0.071) per person year.CONCLUSIONS: The event rate of GAHT increased during 2000-2018. Our data suggested high adherence to GAHT.

KW - Adult

KW - Cohort Studies

KW - Denmark/epidemiology

KW - Female

KW - Gender Identity

KW - Humans

KW - Male

KW - Testosterone

KW - Transgender Persons

UR - http://www.scopus.com/inward/record.url?scp=85128273579&partnerID=8YFLogxK

U2 - 10.1111/andr.13181

DO - 10.1111/andr.13181

M3 - Journal article

C2 - 35366390

VL - 10

SP - 885

EP - 893

JO - Andrology

JF - Andrology

SN - 2047-2919

IS - 5

ER -

ID: 79503181